References of "Fardellone, Patrice"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailLong-term treatment of postmenopausal osteoporosis with strontium ranelate: Results at 8 years.
Reginster, Jean-Yves ULg; Bruyère, Olivier ULg; Sawicki, A. et al

in BONE (2009), 45

OBJECTIVES: Strontium ranelate 2 g/day has proven efficacy against vertebral and nonvertebral fracture over 5 years in postmenopausal osteoporosis, though many women require longer-term treatment. This ... [more ▼]

OBJECTIVES: Strontium ranelate 2 g/day has proven efficacy against vertebral and nonvertebral fracture over 5 years in postmenopausal osteoporosis, though many women require longer-term treatment. This article describes the efficacy, safety, and tolerability of this agent over 8 years. METHODS: Postmenopausal osteoporotic women having participated in the 5-year efficacy trials SOTI and TROPOS were invited to enter a 3-year open-label extension study. The results presented here focus on patients who received strontium ranelate for 8 years. RESULTS: At the extension baseline, the population treated for 8 years (n=879; 79.1+/-5.6 years) had femoral neck T-score of -2.61+/-0.71. The cumulative incidences of new vertebral and nonvertebral fractures (13.7% and 12.0%, respectively) over years 6 to 8 were non-statistically different from the cumulative incidences in the first 3 years of the original studies (11.5% and 9.6%). Lumbar spine, femoral neck, and total hip bone mineral density (BMD) increased throughout the 8-year period. Annual relative change in BMD was significant at every visit, except the 8-year visit for femoral neck and total hip BMD. Strontium ranelate was safe and well tolerated over 8 years. CONCLUSIONS: Long-term treatment with strontium ranelate 2 g/day in postmenopausal osteoporotic women leads to continued increases in BMD at all sites. The data also provide some evidence for a sustained antifracture efficacy. [less ▲]

Detailed reference viewed: 100 (31 ULg)
Full Text
Peer Reviewed
See detailCorrélation entre l'augmentation de la densité minérale osseuse et la réduction du risque fracturaire lors d'un traitement par ranélate de strontium
Bruyère, Olivier ULg; Cormier, C.; Fardellone, Patrice et al

in Revue du Rhumatisme (2006, December), 73

Detailed reference viewed: 8 (4 ULg)
Full Text
Peer Reviewed
See detailA new treatment for the reduction of vertebral and non-vertebral fractures in post-menopausal women with osteoporosis
Reginster, Jean-Yves ULg; Brixen, Kim; Bianchi, Gerolamo et al

in Arthritis and Rheumatism (2004, September), 50(number 9 (suppl.)), 291

Detailed reference viewed: 20 (9 ULg)
Full Text
Peer Reviewed
See detailRapid and sustained anti-fracture efficacy of strontium ranelate in postmenopausal osteoporosis
Reginster, Jean-Yves ULg; Sawicki, A.; Devogelaer, Jean-Pierre et al

in Arthritis and Rheumatism (2002, September), 46(number 9 (suppl.)), 584-5

Detailed reference viewed: 18 (0 ULg)